
Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) - Research analysts at Roth Capital issued their Q2 2025 EPS estimates for shares of Sanuwave Health in a research report issued on Tuesday, July 29th. Roth Capital analyst K. Bauser expects that the company will post earnings per share of ($0.09) for the quarter. Roth Capital has a "Buy" rating and a $49.00 price target on the stock. Roth Capital also issued estimates for Sanuwave Health's Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.27 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at $0.07 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $0.84 EPS and FY2027 earnings at $1.72 EPS.
Separately, Wall Street Zen cut shares of Sanuwave Health from a "buy" rating to a "hold" rating in a report on Saturday, May 24th.
View Our Latest Stock Analysis on SNWV
Sanuwave Health Stock Performance
Shares of SNWV stock traded down $0.33 on Thursday, hitting $35.91. The stock had a trading volume of 16,226 shares, compared to its average volume of 52,165. The company's 50 day moving average is $32.68. Sanuwave Health has a 12-month low of $5.21 and a 12-month high of $39.83. The company has a market cap of $307.75 million, a PE ratio of -7.88 and a beta of 1.29.
Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.66) earnings per share for the quarter. The firm had revenue of $9.34 million during the quarter.
Institutional Investors Weigh In On Sanuwave Health
A number of hedge funds have recently modified their holdings of SNWV. Strategic Investment Solutions Inc. IL bought a new position in Sanuwave Health during the first quarter valued at $47,000. Solas Capital Management LLC bought a new position in shares of Sanuwave Health during the 1st quarter worth $20,658,000. AWM Investment Company Inc. purchased a new stake in Sanuwave Health in the 1st quarter worth about $18,153,000. Goldman Sachs Group Inc. bought a new stake in Sanuwave Health in the 1st quarter valued at about $337,000. Finally, Evernest Financial Advisors LLC bought a new stake in Sanuwave Health in the 2nd quarter valued at about $823,000. Institutional investors own 42.53% of the company's stock.
Insider Transactions at Sanuwave Health
In related news, COO Peter Stegagno sold 1,862 shares of the firm's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $27.71, for a total transaction of $51,596.02. Following the completion of the sale, the chief operating officer owned 2,032 shares in the company, valued at approximately $56,306.72. This trade represents a 47.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Iulian Cioanta sold 3,639 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $31.60, for a total transaction of $114,992.40. Following the sale, the insider owned 41 shares of the company's stock, valued at $1,295.60. This trade represents a 98.89% decrease in their position. The disclosure for this sale can be found here. 14.90% of the stock is currently owned by insiders.
About Sanuwave Health
(
Get Free Report)
SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.
Further Reading

Before you consider Sanuwave Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanuwave Health wasn't on the list.
While Sanuwave Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.